Differential gene expression in RA synovial biopsies from responders versus non-responders to adalimumab therapy

ABSTRACT: TNF antagonists are routinely used in severe rheumatoid arthritis (RA) patients who failed conventional DMARD therapy. According to large clinical trials, the three available drugs (adalimumab, infliximab and etanercept) display similar effects in terms of efficacy, tolerability and side effects. These studies also indicate that about 25% of RA patients treated with TNF-antagonists do not display any significant clinical improvement. The aim of this study was to investigate global molecular patterns in synovial biopsies from RA patients obtained 12 weeks after initiation of adalimumab therapy. All patients had rheumatoid arthritis (RA), according to the American College of rheumatology criteria for the diagnosis of RA. They had active disease at the time of initiation of adalimumab thera

ORGANISM(S): Homo sapiens

SUBMITTER: Bernard Lauwerys 

PROVIDER: E-GEOD-15602 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress